Drug Database
ER

erythropoietin beta (CinnaPoietin ß / CinnaPoietin)

✓ Approved

Cinnagen Co · EPOR · Recombinant Proteins

What is erythropoietin beta?

erythropoietin beta is a recombinant proteins developed by Cinnagen Co. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or subcutaneous injection.

Drug Profile

Brand NamesCinnaPoietin ß, CinnaPoietin
CompanyCinnagen Co
Drug ClassRecombinant Proteins
Molecular TargetEPOR
RouteInjectable (Others), Intravenous (IV), Subcutaneous Injection
StatusApproved

Mechanism of Action

Molecular Targets

erythropoietin beta acts on 1 molecular target:

EPORerythropoietin receptor (EPO-R)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

erythropoietin beta is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Blood and lymphatic system disordersAnaemia✓ Approved
Blood and lymphatic system disordersNephrogenic anaemia✓ Approved

Related Research Articles

PubMedFood chemistry: X2026-09-20

Structural optimization and freeze-thaw stabilization of carnauba wax and beta-sitosterol bigels via peanut protein and sodium alginate complexation.

Hu Chun C, Li Chunyu C, Zhang Weinong W, He Junbo J et al.

This study investigated the influence of peanut protein/sodium alginate (PP/SA) complex and oleogel-to-hydrogel ratio on the structure, mechanical properties and stability of carnauba wax/β-sitosterol-based bigels. The results indicated adding SA increased PP mean particle size from 88.1 to 395.2 and 729.6 nm, and absolute zeta-potential from 38.5 to 53.0 and 60.5 mV, and improved its surface hydrophobicity. Additionally, at 40% and 50% oleogel, SA addition was shown to improve the performance of PP bigels in water holding capacity, elastic modulus (G'), viscous modulus (G″), textural properties (hardness, springiness, chewiness and gumminess), as well as physical and freeze-thaw stability. Notably, the bigels with 50% oleogel exhibited the most compact structure and optimal functional properties. However, at 60% oleogel, the PP bigels declined in texture parameters, rheological properties and stability, making the positive effects of SA negligible. These findings provide a theoretical foundation for utilizing PP/SA bigels as potential spreadable sauce substitutes.

PubMedFood science & nutrition2026-09-20

Dietary Supplementation With Lily Bulb Core Extract Improves Feed Efficiency, Meat Quality, and Intestinal Health in Yellow-Feathered Broilers.

Tan Jiawei J, Yin Jiahui J, Fan Xiqing X, Zhang Linyu L et al.

Lily bulb core is an underused by-product of edible lily processing. We hypothesized that dietary supplementation with lily bulb core extract (BHX) would improve growth performance and meat quality and would be accompanied by changes in intestinal morphology, cecal fermentation, and microbiota. A total of 240 one-day-old male yellow-feathered broilers were assigned to four dietary treatments with six replicate cages of 10 birds each: a basal diet (CON) or the basal diet supplemented with 300, 600, or 900 mg/kg BHX for 53 days. All BHX treatments increased average daily gain over days 1-53, whereas 300 and 600 mg/kg reduced the feed conversion ratio compared with CON. Cooking loss in both breast and leg muscles was lower at 600 and 900 mg/kg than in CON. The duodenal villus-height-to-crypt-depth ratio was increased at 300 and 600 mg/kg. Cecal butyrate increased in all BHX groups and reached the highest concentration at 900 mg/kg. Overall alpha and beta diversity did not differ significantly among treatments, although selected bacterial genera differed among groups. BHX improved several production, meat-quality, and intestinal traits, with 600 mg/kg producing the most consistent overall response under the present experimental conditions.

PubMedOpen forum infectious diseases2026-09-20

Clinical Characteristics and Outcomes of Invasive Listeria Monocytogenes Infection: A 45-Year Retrospective Study at a US Tertiary Center.

Samreen Ayesha A, Alejandra Mendoza Maria M, Vaillant James J JJ, Abu Saleh Omar O

Invasive listeriosis remains a leading cause of foodborne infection-related mortality in the United States and is associated with substantial case fatality despite appropriate antimicrobial therapy. Owing to the relative rarity of invasive disease, contemporary data evaluating clinical characteristics, optimal antimicrobial strategies, and predictors of mortality remain limited. We conducted a retrospective cohort study of adults with laboratory-confirmed invasive Listeria monocytogenes infection at Mayo Clinic Health System sites from 1980 to 2024. Clinical syndromes were categorized into 4 mutually exclusive categories, namely bloodstream infection, central nervous system infection, pregnancy-associated infection, and other focal infections. The primary outcome was 1-year all-cause mortality. Secondary outcomes included 90-day mortality and residual neurological deficits among patients with neurolisteriosis. Fifty patients were included (median age, 72 years; 56% immunocompromised). The most common clinical presentations were bacteremia (44%) and neurolisteriosis (36%), followed by endovascular infection (12%) and peritonitis (6%). Most patients received a beta-lactam-based regimen, 46% aminopenicillin monotherapy, and 30% received combination therapy with gentamicin. Thirty-day, 90-day, and 1-year mortality were 10%, 12%, and 20%, respectively. Immunocompromised status and intensive care unit admission were associated with an increased risk of 1-year mortality, whereas adjunctive gentamicin therapy was not associated with improved survival. Invasive listeriosis is associated with substantial morbidity and mortality, particularly among immunocompromised hosts. Host factors and severity of illness at presentation appear to be key drivers of unfavorable outcomes. Larger multicenter studies are needed to define optimal management strategies.

PubMedCureus2026-09-20

Thymic Carcinoma Presenting as Diffuse Bone Marrow Infiltration Mimicking Lymphoma.

Mateus Farias Krystel P KP, Reyes Mayaute Edgar R ER, Tarazona Cervantes Walmer M WM, Pozo Morales Carmen R CR et al.

Thymic epithelial tumors (TETs) represent the most common primary neoplasms of the anterior mediastinum, yet thymic carcinoma (TC) stands out as an exceptionally rare and biologically aggressive subtype. Unlike thymomas, TCs exhibit marked cytologic atypia, early invasive potential, and a high predisposition for extrathoracic metastasis. We report the case of a 59-year-old male who presented with a seven-month history of progressive, refractory lumbar pain and functional limitation. Initial clinical and laboratory evaluation revealed normocytic anemia, leukocytosis, elevated inflammatory markers, and increased lactate dehydrogenase and beta-2 microglobulin levels. These findings, combined with systemic bone marrow infiltration observed on spinal magnetic resonance imaging, initially suggested a lymphoproliferative disorder. A subsequent thoracic computed tomography scan identified an anterior mediastinal mass with lymphadenopathy. A bone marrow biopsy evidenced infiltration by a poorly differentiated malignant neoplasm, and an immunohistochemical profile of the mediastinal mass confirmed the diagnosis of stage IVb TC, showing positivity for pan-cytokeratin, tumor protein p63, cluster of differentiation 5 (CD5), epithelial membrane antigen (EMA), and cluster of differentiation 117 (CD117), with a Ki-67 proliferation index of 20%, while remaining negative for hematolymphoid, neuroendocrine, and lung-specific markers. The patient was managed through a multidisciplinary approach with systemic palliative chemotherapy. This case highlights a critical diagnostic challenge where TC mimicked a hematological malignancy. The systemic dissemination of TC, particularly the diffuse bone marrow infiltration, is a rare clinical phenotype that obscures the primary mediastinal origin. Our report emphasizes the necessity of including TC in the differential diagnosis of patients presenting with refractory bone pain and systemic hematological abnormalities, even in the absence of respiratory symptoms. Early diagnostic recognition through strategic immunohistochemical profiling is imperative to avoid clinical bias, prevent the initiation of inappropriate therapies, and facilitate a prompt, evidence-based management strategy for patients with advanced, non-resectable disease.

PubMedCureus2026-09-20

Optimizing Infection Risk in Primary Total Knee Arthroplasty: A Narrative Review of Current Concepts, Controversies, and Evidence Gaps.

Salazar Mathias S MS, Almeida Lisbeth T LT

Periprosthetic joint infection (PJI) remains one of the most serious complications following primary total knee arthroplasty (TKA), despite its relatively low incidence. Prevention requires addressing multiple interacting factors related to patient characteristics, microbial burden, antimicrobial prophylaxis, operative technique, and postoperative wound management. The objective of this review is to synthesize contemporary evidence on strategies for reducing infection risk in primary TKA, with particular emphasis on clinically actionable interventions, areas of controversy, and current evidence gaps. This narrative review integrated evidence from the source manuscript and its supporting evidence base, prioritizing TKA-specific systematic reviews, meta-analyses, randomized controlled trials, registry studies, large observational cohorts, clinical guidelines, and implementation studies. Evidence was evaluated according to study design, TKA relevance, consistency of findings, susceptibility to confounding, and applicability to current clinical practice. No de novo systematic search, formal risk-of-bias assessment, or meta-analysis was performed. Current evidence supports structured preoperative risk assessment and optimization, Staphylococcus aureus screening and decolonization, avoidance of intra-articular injections within three months before TKA when feasible, timely cefazolin-based systemic prophylaxis in patients without true contraindications, and stewardship-conscious antibiotic duration. Standardized antiseptic skin preparation and irrigation, efficient operative workflow, meticulous wound management, and early surveillance are also supported as components of a comprehensive prevention strategy. However, several controversies remain. Body mass index, glycemic control, nutritional status, anemia, and smoking are established risk markers, but evidence is insufficient to define universal thresholds for postponing surgery. Cefazolin remains the preferred prophylactic agent, although the optimal regimen for patients with true beta-lactam allergy or resistant-organism risk remains uncertain. Extended oral antibiotic prophylaxis may benefit selected high-risk patients but lacks sufficient evidence for routine use. Evidence regarding antibiotic-loaded bone cement and intraosseous antibiotic prophylaxis remains heterogeneous. Recent randomized evidence does not support routine intrawound vancomycin powder in primary TKA because it did not reduce infection and was associated with more minor wound complications. Persistent wound drainage also remains incompletely standardized in terms of escalation and surgical intervention. Infection prevention in primary TKA should be approached as a risk-stratified perioperative pathway rather than as a single intervention or universal checklist. Current evidence favors systematic host optimization, microbial-burden reduction, appropriate systemic prophylaxis, standardized antisepsis, efficient high-quality surgery, and structured wound surveillance, while selective use of controversial adjuncts should be guided by patient risk and local protocols. Future research should prioritize registry-nested randomized trials, standardized definitions of high-risk patients, procedure-specific outcomes, antimicrobial-stewardship measures, cost-effectiveness, and implementation studies evaluating complete perioperative prevention bundles.

PubMedVeterinary surgery : VS2026-09-19

Trial of erythropoietin and platelet rich plasma as adjunctive treatment in dogs with paraplegia and absent pan perception after thoracolumbar intervertebral disc extrusion and surgical decompression: A clinical pilot study.

Janzen Madison M, Faissler Dominik D, Rozanski Elizabeth E, Kowaleski Michael P MP

To assess the effectiveness of adjunctive treatment with either systemic erythropoietin or local platelet rich plasma administered at the time of decompressive surgery in dogs with severe spinal cord injury (SCI). Prospective randomized study. A total of 32 client owned dogs presented for acute onset of paraplegia and loss of pain perception after a thoracolumbar disc extrusion. All dogs underwent a standard laminectomy within 24 h after admission and were randomly assigned to one of the following treatment groups: (1) Subarachnoid saline (controls), (2) subarachnoid autologous platelet rich plasma (PRP), or (3) subarachnoid saline plus IV erythropoietin (EPO). Examinations were performed initially at the time of admission, and 1, 3, 7-, 14-, 42-, and 84-days post-surgery. Parameters of interest included return of pain perception, motor or ambulatory function, and fecal or urinary continence. Statistical analysis was performed with SPSS for Windows 30 software with p < .05. The median age of the 32 dogs enrolled was 5 years (3-12.5 years). Dachshunds were the most common breed. One dog (3.1%) developed myelomalacia 4 days post-surgery and was euthanized. Three months post-surgery, 24/32 (75%) dogs regained ambulatory function whereas 7/32 (21.8%) did not. There was no overall difference among groups. Dogs treated with EPO appeared to have a trend towards a reduction in incontinence (Fisher exact test, p = .089) but a larger study is needed to verify this apparent finding. The use of EPO might be beneficial to reduce the likelihood of incontinence, but the low number of patients prohibits definitive conclusions. There was no statistically significant clinical benefit found associated with local application of PRP and systemic injection of EPO at the time of decompressive surgery.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about erythropoietin beta